


Sir:



Customer No. 22,852 Attorney Docket No. 2356.0011-10

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Marc ALIZON et al.	) Group Art Unit: 1648
Application No.: 10/076,370	) Examiner: Not yet assigned
Filed: February 19, 2002	) Confirmation No. 2811
For: A VARIANT OF LAV VIRUSES	RECEIVED
Commissioner for Patents Washington, DC 20231	MAY 2 0 2002 TECH CENTER 1600/2900

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING **NUCLEOTIDE SEQUENCE AMINO ACID SEQUENCE DISCLOSURES** 

This paper is filed in response to the Notice dated April 24, 2002.

Applicants submit that this application does not need to comply with the Sequence Rules because its effective U.S. filing date is April 13, 1987, the filing date of Application No. 07/038,330 (now U.S. Patent No. 5,030,714). The Sequence Rules 37 C.F.R. §§ 1.821-1.825 are not effective for applications whose effective U.S. filing date is prior to October 1, 1990. Accordingly, no sequence listing is required

If there is any fee due in connection with the filing of this response, please charge the fee to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.


Dated: May 16, 2002

becca Muleell Bv:

Rebecca M. McNeill Reg. No. 43,796

FINNEGAN **HENDERSON** FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/076,370

02/19/2002

Marc Alizon

2356-0011-10000

CONFIRMATION NO. 2811

22852
FINNEGAN, HENDERSON, FARABOW, GARRETT &
DUNNER LLP
1300 I STREET, NW
WASHINGTON, DC 20005

RECEIVED OCCORDO 0000 7945687

FORMALITIES LETTER

MANUALITIES LETTER

OCC000000007945687\*

MAY 2 0 2002

**TECH CENTER 1600/2900** 

Date Mailed: 04/24/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE